Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine
Kardiovaskuläre, neurologische und immunologische unerwünschte Ereignisse und der 23-valente Pneumokokken-Polysaccharid-Impfstoff
JAMA Network Open · 22.01.2024 · 7 (1) · e2352597
DOI: 10.1001/jamanetworkopen.2023.52597 ↗Auf einen Blick
Bei 4.355 älteren Geimpften zeigte sich nach PPSV23 kein relevanter Anstieg der meisten kardiovaskulären, neurologischen oder immunologischen Ereignisse.
Fragestellung
Besteht bei älteren Erwachsenen nach PPSV23 ein Zusammenhang mit kardiovaskulären, neurologischen oder immunologischen unerwünschten Ereignissen?
Methode
Populationsbasierte Kohortenstudie mit Self-controlled risk interval Design; Datenbankverknüpfung in Korea 2018 bis 2021; Analyse mit konditionaler Poisson-Regression.
Ergebnisse
Unter PPSV23 fanden sich keine signifikanten Assoziationen für Myokardinfarkt (IRR 0,96; 95 %-KI 0,81–1,15), Herzinsuffizienz (0,85; 0,70–1,04), Schlaganfall (0,92; 0,84–1,02), Bell-Lähmung (0,95; 0,72–1,26), Guillain-Barré-Syndrom (0,27; 0,06–1,17), Sepsis (0,99; 0,74–1,32) oder Thrombozytopenie (1,18; 0,60–2,35).
Schlussfolgerung der Autor:innen
In dieser Studie zeigte sich nach PPSV23 kein erkennbarer Anstieg des Risikos für die meisten kardiovaskulären, neurologischen oder immunologischen unerwünschten Ereignisse.
Kernaussagen
- 4.355 ältere Geimpfte mit mindestens einem Ereignis wurden eingeschlossen
- Keine signifikante Risikoerhöhung für die berichteten Outcomes
- IRR z. B. für Myokardinfarkt 0,96; für Schlaganfall 0,92
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 22.01.2024. Verfasst von Dongwon Yoon und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, South Korea. Hauptthemen laut MEDLINE: Bell Palsy, Guillain-Barre Syndrome, Heart Failure, Myocardial Infarction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
Importance Despite widespread immunization with the 23-valent pneumococcal polysaccharide vaccine (PPSV23), safety concerns remain owing to a lack of statistical power and largely outdated evidence.
Objective
To evaluate the association between cardiovascular, neurological, and immunological adverse events and PPSV23 vaccination in older adults. Design, Setting, and Participants This population-based cohort study using a self-controlled risk interval design used a large linked database created by linking the Korea Immunization Registry Information System and the National Health Information Database (2018 to 2021). Participants included patients aged 65 years or older with a history of PPSV23 vaccination and incident cardiovascular, neurological, or immunological events during the risk and control intervals. Data were analyzed from November 2022 to April 2023. Exposure 23-valent pneumococcal polysaccharide vaccine. Main Outcomes and Measures The occurrence of 1 among 6 cardiovascular events (myocardial infarction, atrial fibrillation, cardiomyopathy, heart failure, hypotension, and myocarditis or pericarditis), 2 neurological events (Bell palsy and Guillain-Barré syndrome), and 3 immunological events (sepsis, thrombocytopenia, and anaphylaxis) during the risk and control periods. The risk and control intervals were defined as 1 to 28 and 57 to 112 days after PPSV23 vaccination, respectively. Conditional Poisson regression was used to estimate the incidence rate ratio (IRR) with a 95% CI.
Results
Altogether, 4355 of the 1 802 739 individuals who received PPSV23 vaccination and experienced at least 1 outcome event were included (mean [SD] age, 72.4 [8.2] years; 2272 male participants [52.1%]). For cardiovascular events, there were no significant associations for myocardial infarction (IRR, 0.96; 95% CI, 0.81-1.15), heart failure (IRR, 0.85; 95% CI, 0.70-1.04), and stroke (IRR, 0.92; 95% CI, 0.84-1.02). Similarly, no increased risks were observed for neurological and immunological outcomes: Bell palsy (IRR, 0.95; 95% CI, 0.72-1.26), Guillain-Barré syndrome (IRR, 0.27; 95% CI, 0.06-1.17), sepsis (IRR, 0.99; 95% CI, 0.74-1.32), and thrombocytopenia (IRR, 1.18; 95% CI, 0.60-2.35). Conclusions and Relevance In this self-controlled risk interval study, there was no appreciable increase in risk for most cardiovascular, neurological, or immunological adverse events following PPSV23. The updated safety profile of PPSV23 provides supportive evidence for the establishment of immunization strategies for older adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Sungkyunkwan University, South Korea.
- Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, South Korea.
- School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, South Korea.
- Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, South Korea.
Zitieren
APA
Yoon, D., Jeon, H. L., Kim, J. H., Lee, H., & Shin, J. Y. (2024). Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine. JAMA Network Open, 7(1), e2352597. https://doi.org/10.1001/jamanetworkopen.2023.52597
Vancouver
Yoon D, Jeon HL, Kim JH, Lee H, Shin JY. Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine. JAMA Network Open. 2024;7(1):e2352597. doi:10.1001/jamanetworkopen.2023.52597
BibTeX
@article{Yoon2024,
author = {Yoon, Dongwon and Jeon, Ha-Lim and Kim, Ju Hwan and Lee, Hyesung and Shin, Ju-Young},
title = {Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {1},
pages = {e2352597},
doi = {10.1001/jamanetworkopen.2023.52597}
}
EUVIMED